There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN – Research Report), Regeneron (REGN – Research Report) and Warby Parker (WRBY – Research Report) with bullish sentiments.
Agenus (AGEN)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus on January 17 and set a price target of $6.00. The company’s shares closed last Monday at $0.59, close to its 52-week low of $0.53.
According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agenus with a $6.67 average price target.
See the top stocks recommended by analysts >>
Regeneron (REGN)
Leerink Partners analyst David Risinger maintained a Buy rating on Regeneron on January 17 and set a price target of $1041.00. The company’s shares closed last Monday at $942.22, close to its 52-week high of $943.00.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $976.42, a 4.3% upside from current levels. In a report issued on January 12, RBC Capital also upgraded the stock to Buy with a $1076.00 price target.
Warby Parker (WRBY)
Piper Sandler analyst Edward Yruma assigned a Buy rating to Warby Parker on January 17 and set a price target of $22.00. The company’s shares closed last Monday at $13.24.
According to TipRanks.com, Yruma is a 5-star analyst with an average return of
Currently, the analyst consensus on Warby Parker is a Moderate Buy with an average price target of $17.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AGEN:
